We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
2025 was another turbulent year for Azenta (AZTA - Free Report) stock, which fell more than 30% as the medical solutions provider struggled with ongoing sales weakness. Azenta’s struggles have been highlighted by both short-term performance issues and longer-term structural challenges.
The extended underperformance has led to reduced investor confidence and selling pressure, with Azenta appearing to lose its mojo regarding its services for drug development, clinical research, and advanced cell therapies.
Even with occasional rebounds, the overall momentum remains weak for Azenta stock, and analysts have expressed caution about the company’s ability to outperform going forward.
Image Source: Zacks Investment Research
Revenue Weakness & Market Uncertainty
Azenta’s challenges appear to be tied to fundamental business softness, especially in key revenue segments. Although Azenta was able to reach EPS expectations of $0.21 for its most recent fiscal fourth quarter and edged sales estimates of $156.67 million, the market's positive reaction was short-lived as its top line contracted from $170 million in the prior year quarter.
To that point, Azenta has had difficulties in regard to sustaining its annual revenue above $500 million, as shown below. Furthermore, Azenta has warned of continued uncertainty in the macro environment, particularly around capital spending from its customers, which typically includes biotech firms as well as gene and cell therapy companies.
Image Source: Zacks Investment Research
Declining EPS Revisions
Justifying the market’s concerns is that Azenta's current fiscal 2026 and FY27 EPS estimates have declined over 10% in the last 60 days, respectively.
And at $34 a share, Azenta stock still isn’t cheap in terms of its forward P/E multiple of 46X, a sharp premium to the benchmark S&P 500’s 26X despite vastly underperforming the broader market in recent years.
Image Source: Zacks Investment Research
Bottom Line
Until Azenta demonstrates sustained revenue growth or operational improvements, its stock may continue to face pressure. Correlating with such, AZTA currently lands a Zacks Rank #5 (Strong Sell) and has been a notable stock to avoid going into 2026.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bear of the Day: Azenta (AZTA)
2025 was another turbulent year for Azenta (AZTA - Free Report) stock, which fell more than 30% as the medical solutions provider struggled with ongoing sales weakness. Azenta’s struggles have been highlighted by both short-term performance issues and longer-term structural challenges.
The extended underperformance has led to reduced investor confidence and selling pressure, with Azenta appearing to lose its mojo regarding its services for drug development, clinical research, and advanced cell therapies.
Even with occasional rebounds, the overall momentum remains weak for Azenta stock, and analysts have expressed caution about the company’s ability to outperform going forward.
Image Source: Zacks Investment Research
Revenue Weakness & Market Uncertainty
Azenta’s challenges appear to be tied to fundamental business softness, especially in key revenue segments. Although Azenta was able to reach EPS expectations of $0.21 for its most recent fiscal fourth quarter and edged sales estimates of $156.67 million, the market's positive reaction was short-lived as its top line contracted from $170 million in the prior year quarter.
To that point, Azenta has had difficulties in regard to sustaining its annual revenue above $500 million, as shown below. Furthermore, Azenta has warned of continued uncertainty in the macro environment, particularly around capital spending from its customers, which typically includes biotech firms as well as gene and cell therapy companies.
Image Source: Zacks Investment Research
Declining EPS Revisions
Justifying the market’s concerns is that Azenta's current fiscal 2026 and FY27 EPS estimates have declined over 10% in the last 60 days, respectively.
And at $34 a share, Azenta stock still isn’t cheap in terms of its forward P/E multiple of 46X, a sharp premium to the benchmark S&P 500’s 26X despite vastly underperforming the broader market in recent years.
Image Source: Zacks Investment Research
Bottom Line
Until Azenta demonstrates sustained revenue growth or operational improvements, its stock may continue to face pressure. Correlating with such, AZTA currently lands a Zacks Rank #5 (Strong Sell) and has been a notable stock to avoid going into 2026.